A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

STAMPEDE2 is a clinical trial comparing two new treatments with standard of care in people with prostate cancer that has spread to other parts of the body and is responsive to hormone therapy. People from all backgrounds and ethnicities are encouraged to take part and multiple hospitals across the UK are involved. University College London is running the trial. Each comparison within the trial has its own control arm where people get the best standard of care (Arm A) versus a research arm where a new treatment is added to standard of care. Participants are allocated to an arm by a computeris

Trial Details

NCT ID
NCT06320067
Phase
PHASE3
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • Stereotactic Ablative Body Radiotherapy (SABR)
  • 177Lu-PSMA-617
  • Androgen Deprivation Therapy (ADT)
  • Androgen Receptor Signalling Inhibitor (ARPI)
  • Radiotherapy to Prostate ± Pelvic Nodes
  • Docetaxel
Locations (sample)
  • Barnsley, United Kingdom|53.55,-1.48333
  • Cambridge, United Kingdom|52.2,0.11667
  • Exeter, United Kingdom|50.7236,-3.52751
  • Exeter, United Kingdom|50.7236,-3.52751
  • Harlow, United Kingdom|51.77655,0.11158

Key Eligibility Criteria

  • At least 18 years old.
  • Histological confirmation of prostate adenocarcinoma or a strong clinical suspicion of prostate cancer with a plan to confirm the diagnosis formall…
  • Confirmation of metastatic site(s) on CT/MRI and either bone or PET scan. Patients with metastatic disease meeting any of the following criteria ar…
  • Metastatic disease to the bone (in any distribution).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →